Pharmacodynamic Modeling Overview

Principles

Definition

Pharmacodynamic modeling is a quantitative methodological approach that employs mathematical and statistical models to characterize the relationship between drug exposure (e.g., concentration) and the magnitude and time course of its pharmacological or clinical effects. This field is crucial for understanding mechanisms of drug action, predicting therapeutic outcomes, and guiding rational drug development and dosing strategies.

Ontological type

Link to Pharmacokinetics

Core Models

Model Development Workflow

Key developments

Key Figures

Quantitative PK/PD Foundations era

William M. Pardridge[1] was active during this era with affiliations at the Massachusetts Institute of Technology[2] and Stanford University[3]. His key contribution, the 1977 paper KINETICS OF COMPETITIVE INHIBITION OF NEUTRAL AMINO ACID TRANSPORT ACROSS THE BLOOD-BRAIN BARRIER[4], established quantitative models of transporter kinetics and brain exposure that provided mechanistic insight for interpreting concentration–effect relationships in the CNS. Pardridge[1] helped bridge physiology and pharmacology in a way that laid groundwork for later PK/PD concepts, including receptor occupancy thinking and mechanistic indirect‑response reasoning in this era. This work continued to influence the era by highlighting transport barriers as determinants of exposure, reinforcing the quantitative foundations of PK/PD that supported emergence of population-based modeling and covariate‑driven prediction[1].

Translational Model-Based Development era

Mats O. Karlsson [1] was a key figure in the Translational Model-Based Development era, with affiliations at Karolinska Institutet [3] and Universidad de Navarra [4]. Xpose, an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM [7], a key contribution of this era, streamlined PK/PD model development and promoted broader adoption of model-based translation. Alan Forrest [2] contributed to antimicrobial PK/PD modeling during this era, with affiliations at Harvard University [5] and University of California, San Francisco [6]. His 2006 paper Antimicrobial Resistance: Pharmacokinetics-Pharmacodynamics of Antimicrobial Therapy: It's Not Just for Mice Anymore [8] illustrated how PK/PD indices bridge preclinical findings and clinical regimens, a cornerstone of translational MBPD practice.

Computational Mechanistic Integration era

Representative authors in this era include Rowland and Tozer, whose PBPK/PD framework continues to guide physiologically grounded target engagement predictions. Hartmut Derendorf's work on population PK/PD modeling and model-informed drug development emphasized regulatory-grade workflows and cross-species translation. Paul C. Jusko contributed quantitative PD modeling and systems pharmacology approaches that connect molecular mechanisms to clinical effects, strengthening translational pharmacodynamics. Together, these leaders and other pharmacometrics and systems pharmacology researchers have increasingly integrated machine learning, structural modeling, residence-time metrics, and genetic causal inference within mechanistic PK/PD frameworks to enhance predictive accuracy and inform study design.